Mesoblast is developing a series of high margin, off the shelf adult stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in potentially thousands of unrelated, or allogeneic, recipients at the time and place of need.
Quote | Mesoblast Ltd Ord (OTCMKTS:MEOBF)
Last: | $0.66 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.66 |
High: | $0 |
Low: | $0 |
Volume: | 201,075 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Mesoblast Ltd Ord (OTCMKTS:MEOBF)
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Applicati...
Message Board Posts | Mesoblast Ltd Ord (OTCMKTS:MEOBF)
Subject | By | Source | When |
---|---|---|---|
chartguy89: MEOBF 5.19 Stock Charts $MEOBF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 6:46:31 PM |
chartguy89: MEOBF Stock Charts Last: -0.13 Thursday, February 27, 2014 at 10:28:22 PM $MEOBF | chartguy89 | investorshangout | 02/28/2014 3:28:33 AM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Applicati...
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. Mesoblast Chief Executive Silviu Itescu said: ȁ...